In line with her commitment to add value to lives, Fidson Healthcare Plc. has expanded its portfolio of ethical products by introducing two new products namely Cresidox and Gibitor.
Cresidox is an anti-hypertensive that is efficient in slowing down the progression of heart failure. It is a brand of carvedilol, a beta-blocking agent patented in 1978 for the treatment of high blood pressure, congestive heart failure, and left ventricular dysfunction in people who are otherwise stable. Cresidox is available in 6.25mg & 12.5mg.
On the other hand, Gibitor is an anticonvulsant suitable for effective treatment of epilepsy, post-herpetic neuralgia, and neuropathic pain. As a brand of gabapentin, it is an efficient medication to prevent and control seizures. Gibitor is available in 300mg.
It would interest you to know that epilepsy has been identified as a major risk factor for Sudden Cardiac Arrest (SCA) which is a major cause of sudden death.1 Cresidox and Gibitor if administered as prescribed by a health professional could ultimately reduce the incidence of death.
The introduction of Cresidox and Gibitor further strengthens Fidson’s position as a leader in Nigeria’s pharmaceutical sector.
Reference:
1 PubMed Central® (PMC) of the U.S. National Institutes of Health’s National Library of Medicine (NIH/NLM).